YYZ Pharmatech Inc.
Michael Badeau has a varied background in the finance industry, with experience in asset management, client services, and regional management. Currently serving as the Managing Director at Wendsley Lake Corporation and the President & Chief Operating Officer at YYZ Pharmatech Inc., Michael has also held roles at Bridgehouse Asset Managers and Brandes Investment Partners. With a Bachelor of Arts in History from King's University College, Michael continues to excel in leadership roles within the industry.
This person is not in any teams
YYZ Pharmatech Inc.
YYZ Pharmatech has created enabling technologies that overcome three fundamental challenges in modern medicine: 1) Harness blood as the most data rich sample type 2) Identify low-abundance markers of disease 3) Develop ultra-sensitive assays against the most biologically significant biomolecules About YYZ Pharmatech: YYZ builds innovative technology platforms to enable new insights in modern medicine, with breakthroughs in the ultra-sensitive discovery & measurement of biomolecules. Supported by over 20 years of published research and backed by two visionary family offices, YYZ’s technology suite is powered by: DPiPSA™ for Discovery: (Database-Driven Proteome Intact Partition Statistical Analysis) Unbiased & statistically rigorous bioinformatics for next-generation discovery & stratification. ELiMSA™ for Measurement: (Enzyme Linked Mass Spectrometric Assay) Ultra-sensitive & quantitative assay technology with extensive life science applications. YYZ is the commercialization partner of the Marshall Team at Toronto Metropolitan University (formerly Ryerson University).